Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine

Xenobiotica

Volumn 43, Issue 7, 2013, Pages 636-640

  Choi, Chang Ik ^a   Bae, Jung Woo ^b   Keum, Seul Ki ^a   Lee, Yun Jeong ^a,c   Lee, Hye In ^a   Jang, Choon Gon ^a   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Keimyung University   (South Korea)

^c Dankook University   (South Korea)

Author keywords

Genetic polymorphism; Lamivudine; OCT2; Pharmacogenomics; Pharmacokinetics

Indexed keywords

LAMIVUDINE;

ARTICLE; DRUG BLOOD LEVEL; DRUG EXCRETION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KIDNEY CLEARANCE; KOREA; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM MASS SPECTROMETRY; URINARY EXCRETION;

ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, LIQUID; GENOTYPE; HUMANS; LAMIVUDINE; ORGANIC CATION TRANSPORT PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878889895     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.747710     Document Type: Article

References (33)

1. Allen JD, Schinkel AH. (2002). Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1:427-34.
2. Allikmets R, Schriml LM, Hutchinson A, et al. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-9. (Pubitemid 28551112)
3. Anderson PL, Lamba J, Aquilante CL, et al. (2006). Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 42:441-9. (Pubitemid 44050891)
4. Chen Y, Li S, Brown C, et al. (2009). Effect of genetic variation in the OCT2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497-504.
5. Choi MK, Song IS. (2012). Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos 33:170-8.
6. Doong SL, Tsai CH, Schinazi RF, et al. (1991). Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-9. (Pubitemid 21915383)
7. Epivir® (lamivudine) prescribing information. GlaxoSmithKline. Research Triangle Park, NC, USA, 2011.
8. Fukushima-Uesaka H, Maekawa K, Ozawa S, et al. (2004). Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 19:239-44.
9. Gorboulev V, Ulzheimer JC, Akhoundova A, et al. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871-81. (Pubitemid 27332696)
10. Heald AE, Hsyu PH, Yuen GJ, et al. (1996). Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 40:1514-19. (Pubitemid 26169059)
11. Johnson MA, Moore KH, Yuen GJ, et al. (1999). Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36:41-66. (Pubitemid 29056000)
12. Jung N, Lehmann C, Rubbert A, et al. (2008). Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36:1616-23.
13. Jung N, Lehmann C, Rubbert A, et al. (2012). Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection. Available from: http://link.springer.com/ article/10.1007%2Fs15010-012-0308-8 [last accessed 29 Oct 2012].
14. Kang HJ, Song IS, Shin HJ, et al. (2007). Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 35:667-75.
15. Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharma-ceutical implications. Pharm Res 24:1227-51. (Pubitemid 46876495)
16. Kurata T, Muraki Y, Mizutani H, et al. (2010). Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet 25:328-34.
17. Minuesa G, Volk C, Molina-Arcas M, et al. (2009). Transport of lamivudine [(-)-beta-L-2', 3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252-61.
18. Moore KH, Yuen GJ, Raasch RH, et al. (1996). Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 59:550-8.
19. Motohashi H, Sakurai Y, Saito H, et al. (2002). Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-74. (Pubitemid 34274082)
20. Nies AT, Koepsell H, Winter S, et al. (2009). Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227-40.
21. Ogasawara K, Terada T, Motohashi H, et al. (2008). Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 53:607-14.
22. Okuda M, Saito H, Urakami Y, et al. (1996). cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 224:500-7. (Pubitemid 26268216)
23. Schuetz JD, Connelly MC, Sun D, et al. (1999). MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-51. (Pubitemid 29439577)
24. Song IS, Shin HJ, Shim EJ, et al. (2008). Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559-62.
25. Soudeyns H, Yao XI, Gao Q, et al. (1991). Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 35:1386-90.
26. Takubo T, Kato T, Kinami J, et al. (2000). Effect of lamivudine on uptake of organic cations by rat renal brush-border and basolateral membrane vesicles. J Pharm Pharmacol 52:569-75. (Pubitemid 30319162)
27. Takubo T, Kato T, Kinami J, et al. (2002). Uptake of lamivudine by rat renal brush border membrane vesicles. J Pharm Pharmacol 54:111-17. (Pubitemid 34116230)
28. Turriziani O, Schuetz JD, Focher F, et al. (2002). Impaired 2', 3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 368:325-32. (Pubitemid 35463436)
29. Wada S, Tsuda M, Sekine T, et al. (2000). Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 294:844-9. (Pubitemid 30666832)
30. Wang ZJ, Yin OQ, Tomlinson B, et al. (2008). OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637-45.
31. Wijnholds J, Mol CA, van Deemter L, et al. (2000). Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476-81. (Pubitemid 30431488)
32. Yonezawa A, Masuda S, Nishihara K, et al. (2005). Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70:1823-31. (Pubitemid 41612013)
33. Zolk O, Solbach TF, Konig J, et al. (2009). Functional characterization of the human organic cation transporter 2 variant p.270Ala > Ser. Drug Metab Dispos 37:1312-18.